Correction of the high blood viscosity syndrome by a mixture of Diquertin and Ascorbic Acid in vitro and in vivo.

Abstract

Diquertin was shown to diminish blood viscosity, to decrease the aggregation of erythrocytes, and to increase their deformability using a model of the high blood viscosity syndrome in vitro. A mixture of Diquertin with Ascorbic Acid was more effective in improving rheological indicators of blood, then either Diquertin or Tanakan. On a model of chronic brain ischemia, which is accompanied by significant deterioration of the rheological properties of blood, it was shown that a therapy with a mixture of Diquertin and Ascorbic Acid decreases the expression of the high blood viscosity syndrome.